Phase II Study Of Combination Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer
Latest Information Update: 06 Mar 2025
At a glance
- Drugs Ruxolitinib (Primary) ; Cyclophosphamide; Doxorubicin; Paclitaxel
- Indications Advanced breast cancer; Early breast cancer; HER2 negative breast cancer; Inflammatory breast cancer; Male breast cancer; Triple negative breast cancer
- Focus Pharmacodynamics
Most Recent Events
- 03 Mar 2025 Planned End Date changed from 1 Dec 2024 to 1 Jun 2025.
- 17 Oct 2024 Planned End Date changed from 1 Aug 2024 to 1 Dec 2024.
- 21 Mar 2024 Planned End Date changed from 1 Feb 2024 to 1 Aug 2024.